Luke Miels

Luke joined GSK and the GLT in 2017. As Chief Commercial Officer he is responsible for our commercial portfolio of medicines and vaccines. Luke was appointed CEO Designate on 29 September 2025. He will assume full responsibilities as CEO and join the Board on 1 January 2026. 

Luke co-chairs the Portfolio Investment Board with Tony Wood.

Outside of GSK, Luke is a member of the Singapore Economic Development Board.

He previously worked for AstraZeneca as Executive Vice President of their European business and, prior to that, was Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs. Before that, he was head of Asia for Roche, based in Shanghai and then Singapore. Prior to that he held roles of increasing seniority at Roche and Sanofi-Aventis in the US, Europe and Asia.

Luke holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and a MBA from the Macquarie University, Sydney.